Domestic exports of Europe and the United States need to establish the overall preparations advantage
According to Chinese Medicine & Health Products Import and Export Chamber of Commerce statistics, in 2009 China Western medicine export performance over 1299 enterprises, including foreign-invested enterprises accounted for only Western medicine in China exports about 14% of total number of enterprises, but its export share is as high as 51.92% . Meanwhile, Asia and Africa is still the main export market, China agent, the proportion of total exports to these two areas reached 69.58%, the export of agents in China and other markets in Europe and the United States gains little. At present, domestic market competition intensified, the Chinese pharmaceutical industry urgently needs a wider breathing space and the export of agents seems urgent and unavoidable.
Recently, at the China Medical Management Association international symposium held by the Working Committee, the domestic pharmaceutical companies responsible for more than one person gathered together to solve the successful Chinese medicine preparations to go abroad this Road Industrial proposition.
The road is still far away
Comprehensive Health Insurance Association of China director, said Xu Ming, currently there are 21 pharmaceutical companies in China by the U.S. Food and Drug Administration (FDA), the World Health Organization, Japan and the European Union and other developed markets cGMP certification preparation, there are 4 to 5 also recently certified home soon. Zhejiang Hua Hai Pharmaceutical, Shenzhen Vogue, Shijiazhuang Pharmaceutical Group, Shanghai Pharmaceutical and so on are made of a dozen or even dozens of international certification, and preparation products have been sold to the markets of these countries and regions. However, the reporter did not from their facial expressions and speech, read out "proud" and "show off" means, but more of a "across the glass feel powerless and frustrated," the anxious feelings. Both companies have been certified or are international efforts to "younger", the difficulties are many.
Asymmetric information, so many companies waste their energy, loss of money, at a loss. MA by buying foreign number (production license), is a shortcut preparations international. At the meeting, a company recently said it purchased a MA number, spent 300,000 yuan, and the other companies immediately said they only "spent 30,000 yuan," so the first few seconds to mute the speakers made?? Although there were varieties of bring the price difference between different, but because the information asymmetry so "ignorant" business loss common examples of gold and silver off. No authority to release accurate information to guide enterprises, lack of personnel familiar with international rules of the game, so that enterprises in the dark into the blind area repeatedly.
Certified does not mean that once and for all, the test of the enterprise is just beginning. Always implement the international quality assurance system is not easy. Yiling Pharmaceutical Group, Wei-Dong Jia, director of drug preparation room points to the aspirations of many of the Enterprise: follow-up re-certification is not difficult for small enterprises, in the past that surprise can not cope with chores of. Recertification examination focused on whether companies 3 years consistently implement the quality system standard. Remove all kinds of costly on-site inspection fee, in the three years, the same high maintenance costs of enterprises.
Received certification does not mean that a large number of orders will be heard, "to the market exchange from the product registration, no 2 ~ 3 years is not possible." Jian Li Pharmaceutical Co., Ltd. Shenzhen Qing Ouyang, general manager, said. Moreover, competition in the international market, the domestic pharmaceutical companies to face pressure from the Indian pharmaceutical companies. Indian pharmaceutical companies in the language, marketing, etc. can not be ignored, the current formulations in India accounted for 20% market share in Europe and America.
Logistic problems the industry chain is also one of the constraints. "Internationalization of the hardware required to complete the import, accessories in the country did not meet the European Union certified, there are also all packaging materials imported from Europe and the United States." Wang Biao, deputy general manager of Zhejiang Huahaiyaoye Inc. looked very helpless. Competition Bureau in Beijing Pharmaceutical Co., Ltd. Chairman Chen seems product integration issues must be resolved, accessories, including the supporting material can not be neglected. After all, not only preparation of international cGMP requirements of production processes, increase domestic raw materials, packaging material standards, and international standards in order to better boost to tap into the international market.
Eagerly looked forward to policy support
"Made in China" has swept the world, but the mainstream pharmaceutical market in Europe and the United States is an exception. How to make "Made in China" to the world of medicine? National Federation of Chamber of Commerce vice president of the pharmaceutical industry, said Xie-Long Luo, China's pharmaceutical enterprises in the international market is a common pioneer, "China" only under the overall edge to gain a competitive advantage.
According to Chinese Medicine & Health Products Import and Export Chamber of Commerce statistics, in 2009 China Western medicine export performance of enterprises has reached 1299, of which foreign-invested enterprises accounted for only Western medicine in China exports about 14% of total number of enterprises, but its export share is as high as 51.92% . Meanwhile, Asia and Africa is still the main export market, China agent, the proportion of total exports to these two areas reached 69.58%, China's export of agents of the market in Europe and America gains little. At present, domestic market competition intensified, the Chinese pharmaceutical industry urgently needs a wider breathing space and the export of agents seems urgent and unavoidable.
Recently, at the China Medical Management Association international symposium organized by the Committee work on many domestic pharmaceutical industry executives gathered at a jointly solving the successful Chinese medicine preparations to go abroad this Road Industrial proposition.
The road is still far away
Comprehensive Health Insurance Association of China director, said Xu Ming, currently there are 21 pharmaceutical companies in China by the U.S. Food and Drug Administration (FDA), the World Health Organization, Japan and the European Union and other developed markets cGMP certification preparation, there are 4 to 5 also recently certified home soon. Hua Hai Pharmaceutical Zhejiang, Shenzhen Vogue, Shijiazhuang Pharmaceutical Group, Shanghai Pharmaceutical and so on are made of a dozen or even dozens of international certification, and preparation products have been sold to the markets of these countries and regions. However, the reporter did not from their facial expressions and speech, read out "proud" and "show off" means, but more of a "across the glass feel powerless and frustrated," the anxious feelings. Both companies have been certified or are international efforts to "younger", the difficulties are many.
Asymmetric information, so many companies waste their energy, loss of money, at a loss. MA by buying foreign number (production license), is an international shortcut preparation. At the meeting, a company recently said it purchased a MA number, spent 30 million to another company once said they only "spent 30,000 yuan," so the first few seconds of speakers dumb statement?? Although there were varieties of bring the price difference between different, but because the information asymmetry makes the "ignorant" business loss common examples of gold and silver off. No authority to release accurate information to guide enterprises, lack of personnel familiar with international rules of the game, so that enterprises in the dark into the blind area repeatedly.
Certified does not mean that once and for all, the test of the enterprise is just beginning. Always implement the international quality assurance system is not easy. Yiling Pharmaceutical Group, Wei-Dong Jia, director of drug preparation room points to the aspirations of many of the Enterprise: follow-up re-certification is not difficult for small enterprises, in the past that surprise can not cope with chores of. Re-certification inspection will focus on enterprises in three years whether to consistently implement the quality system standard. Remove all kinds of costly on-site inspection fee, in the three years, enterprises in the same high maintenance costs.
Received certification does not mean that a large number of orders will be heard, "to the market exchange from the product registration, no 2 ~ 3 years is not possible." Jian Li Pharmaceutical Co., Ltd. Shenzhen Qing Ouyang, general manager, said. Moreover, competition in the international market, the domestic pharmaceutical companies to face pressure from the Indian pharmaceutical companies. Indian pharmaceutical companies in the language, marketing, etc. can not be ignored, the current formulations in India accounted for 20% market share in Europe and America.
Logistic problems the industry chain is also one of the constraints. "Internationalization of hardware required to complete the import, accessories in the country did not meet the European Union certified, there are also all packaging materials imported from Europe and the United States." Wang Biao, vice president of Zhejiang Huahaiyaoye Inc. looked very helpless. Competition Bureau in Beijing Pharmaceutical Co., Ltd. Chairman Chen seems product integration issues must be resolved, accessories, including the supporting material can not be neglected. After all, not only preparation of international cGMP requirements of production processes, improve the domestic raw materials, packaging material standards, and international standards in order to better boost to tap into the international market.
Eagerly looked forward to policy support
"Made in China" has swept the world, but in the mainstream European and American pharmaceutical market is an exception. How to make "Made in China" to the world of medicine? National Federation of Chamber of Commerce vice president of the pharmaceutical industry, said Xie-Long Luo, China's pharmaceutical enterprises in the international market is a common pioneer, "China" only under the overall edge to gain a competitive advantage.
Pharmaceutical Co., Ltd. Shandong Rui Bode Qi, general manager of package that should play the "China" brand, the Government's policy to encourage essential. Wang Biao's proposal seems to be more specific: has received international certification of companies want to tender, and prices, can enjoy the original study drug as treatment, the adoption of international certification of product lines produced product should be and the original study drug with the price; in tender at all levels, quality, priority should be to obtain international certification standards, to achieve international sales business tilt, such as single tender or original research and patent expired medicines on the same platform, tender, rather than a list of patents, sales, and quality rankings, etc. related indicators.
Chinese Medical Enterprise Management Association in Matilda believes that the current price management system, certified to meet EU standards on drugs, the price should be consistent with the EU imported drugs. The proportion of the export tax rebate of 17% should be mentioned, to support and encourage enterprises to develop international markets.
Beijing Branch letter will become general manager of Medical Technology Development Co., Ltd. is recommended that countries set up agent Wang Jingang international science and technology projects, select focus areas, key products, organizations and scientific research institutes and enterprises from API to formulations for scientific research, breakthrough, select production technology and strong business separately for industrialization, it can join forces, become a global priority areas of advantage. Meanwhile, we must consolidate the advantages of China's raw material medicine, the development of certified accessories and packaging materials, so as to form industrial advantages.
"Weakening of asymmetric information, the need for specialized business counseling agencies. We hope that Council give full play to the role of integrated enterprise demands a dialogue with the Government, organizations of domestic enterprises to overseas study, the association to become a bridge between business and international links." Beijing Wan Hui Double-Crane Pharmaceutical Co., Ltd. related to appeal. Matilda said in the Chinese Medical Enterprise Management Association recently established a special international working committees, to organize, promote international work.
Long-term work in the UK package Qi suggested, "From now to 2013, nearly 80 billion U.S. dollars in patent medicines will face patent expiration, the scope of the export products should focus on these types of generic drugs on. The world's largest generics company Israel's Teva companies spend heavily on imitation grab these drugs, for listing immediately after the patent expires. "
China's pharmaceutical market for the international problem of low confidence, many participants believe that enhancing the recognition of Chinese preparation is very important. "Going out of business must be a real breakthrough in product quality, to improve the service guarantee system, to enhance self-awareness. While avoiding similar products 'fight bayonets', work together to jointly create a 'China Pharma' brand." Xie Long Luo concluded.
decorative-wall-panel.com is a promising e-commerce company in China. decorative-wall-panel.com offers a variety of high quality products such as Wood texture manufacturer , PVC accessory system decorative wall panel, and many more. For more information, please visit http://www.decorative-wall-panel.com/ today!
Processing your request, Please wait....
